Keyphrases
Chronic Lymphocytic Leukemia
100%
Novel Targeted Therapy
100%
Japanese Patients
100%
Treatment Algorithm
100%
Leukemia Patients
50%
Treatment Strategy
25%
Bcl-2 Antagonist
25%
BTK Inhibitor
25%
Risk Factors
12%
Clinical Practice
12%
High Risk
12%
Combination Therapy
12%
Response to Therapy
12%
Current Treatment
12%
Disease Progression
12%
Conventional Chemotherapy
12%
Japan
12%
New Agents
12%
Heavy Chain
12%
Randomized Clinical Trial
12%
Targeted Agents
12%
Molecular Targeted Therapy
12%
Highly Effective
12%
17p Deletion
12%
Disease Response
12%
Chemoimmunotherapy
12%
Leukemia Risk
12%
Tion
12%
Therapy Approaches
12%
Therapy Decision
12%
IGHV mutation
12%
11q Deletion
12%
Armamentarium
12%
Ibrutinib
12%
Molecular Risk Factors
12%
Individual Risk
12%
Novel Targeted Agents
12%
Free Treatment
12%
Chemotherapy-free
12%
Immunoglobulin Variable Region
12%
Genomic Risk Factors
12%
Venetoclax
12%
Medicine and Dentistry
Targeted Therapy
100%
B-Cell Chronic Lymphocytic Leukemia
100%
Combination Therapy
12%
Disease Exacerbation
12%
Heavy Chain
12%
Randomized Clinical Trial
12%
Molecularly Targeted Therapy
12%
Chemoimmunotherapy
12%
Ibrutinib
12%
IGHV@
12%
Immunoglobulin Variable Region
12%
Venetoclax
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Chemotherapy
25%
Combination Therapy
12%
Immunotherapy
12%
Disease Exacerbation
12%
Immunoglobulin
12%
Randomized Clinical Trial
12%
Ibrutinib
12%
Venetoclax
12%